Matthew Comstock, DO
Interventional Cardiology · Tulsa, OKNPI 1174750749
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.3%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Philips North America LLC at 54.0% of the total. Reporting peaked in 2023 at $18,446 and has fallen 66.2% since, to $6,238 in 2025. Among interventional cardiology clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 749 payments — averaging $92.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$38K
- Cardinal Health 200 LLC$5K
- Biotronik Inc.$5K
- Abbott$4K
- Cordis US CORP.$3K
- Boston Scientific$2K
- plus $13K from 54 others
What the payments were for
- Consulting fees$36,27652%
- Speaking & faculty fees$7,91111%
- Travel & lodging$1,5762%
- Food & beverage$22,01632%
- Education$4221%
- Other$1,2252%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IGT D Peripheral$16,799
- (9520) IGT Devices Undivided$13,420
- (6554) Periph Vasc Undiv$3,375
- Confirm Rx$2,231
- Impella$659
- GENERAL - THERAPIES$472
- Auryon Laser System 100-120 Vac$416
- Turbo Power$348
- Alto Abdominal Stent Graft System$290
- EKOSONIC$274
- Pulsar-18 T3$247
- Passeo-18$247
- (5139) IGT Fixed SV TnM$216
- ENROUTE Transcarotid Neuroprotection System$174
- ENROUTE Transcarotid Stent$174
- Assurity Pacemaker$166
- RotarexS 6 F x 135 cm$165
- INCEPTIV$149
- GORE VIABAHN VBX Balloon Expandable Endo$148
- Indigo System$142
How this compares
$69,425 in reported general payments places this provider in the 90th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 114 | $117,264 |
| EntrestoSacubitril/Valsartan | 63 | $78,745 |
| EliquisApixaban | 48 | $55,593 |
| FarxigaDapagliflozin Propanediol | 34 | $51,875 |
| JardianceEmpagliflozin | 26 | $25,590 |
| Repatha SureclickEvolocumab | 31 | $22,474 |
| ClopidogrelClopidogrel Bisulfate | 862 | $11,689 |
| Rosuvastatin Calcium | 731 | $10,296 |
| Pantoprazole Sodium | 702 | $8,150 |
| BrilintaTicagrelor | 15 | $7,343 |
| Ranolazine ErRanolazine | 51 | $5,908 |
| Nebivolol Hcl | 100 | $5,890 |
| Metoprolol Succinate | 369 | $4,025 |
| Valsartan | 141 | $2,449 |
| Potassium Chloride | 110 | $1,358 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $775 | $117,264114 claims |
| NovartisEntresto | $266 | $78,74563 claims |
| AstraZenecaFarxiga, Brilinta | $440 | $59,21749 claims |
| PfizerEliquis | $42 | $55,59348 claims |
| Boehringer IngelheimJardiance | $305 | $25,59026 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 110 interventional cardiology providers in Oklahoma.
Other interventional cardiology in Tulsa
- Kamran MuhammadTulsa$1.4M
- Stanley ZimmermanTulsa$93K
- Wayne LeimbachTulsa$68K
- Tom HuTulsa$57K
- Eugene IchinoseTulsa$49K
- Poorya FazelTulsa$29K
- Tucker HarrisonTulsa$19K
- Andrew KurklinskyTulsa$15K
- Stewart KatzTulsa$13K
- Arash KarnamaTulsa$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.